Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 16;12:731546. doi: 10.3389/fimmu.2021.731546

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Xu, Zhang, Huang, Dai, Gao, Li, Sheng, Huang, Wang and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Network meta-analysis of SICI, DICI, SICI+CT, DICI+CT, and CT. (A) Pooled hazard ratio (HR) [95% CrIs (credible intervals)] for overall survival (OS) and progression-free survival (PFS) in the overall population. (B) Pooled odds ratio (OR) (95% CrIs) for objective response rate (ORR) and adverse events of grade 3 or higher (≥3AEs) in the overall population. Data in each cell are HR or OR (95% CrIs) for the comparison of upper row-defining treatment vs. lower row-defining treatment. HR less than 1 and OR more than 1 favor upper-row treatment. Significant results are highlighted in red and bold. SICI, single immune checkpoint inhibitor; DICI, double immune checkpoint inhibitors; SICI+CT, single immune checkpoint inhibitor combined with chemotherapy; DICI+CT, double immune checkpoint inhibitors combined with chemotherapy; CT, chemotherapy.